TVRD
Tvardi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.88
+5.96%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.82
From 52W high−82.31%
Volume32261.00
Market cap$11.80M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.82
From 52W high
−82.31%
Volume
32261.00
Market cap
$11.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
34.5
MomentumView details →
1D Return
+5.96%
YTD Return
−80.00%
SummaryUpdated Jun 1, 2026
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) is a clinical-stage biopharmaceutical company founded to develop innovative oral therapies for fibrosis-driven diseases. The company went public in April 2025 and focuses specifically on targeting the STAT3 pathway, a critical cellular signaling mechanism involved in inflammation and tissue scarring. Tvardi's approach centers on developing small molecule drugs that can be taken orally, offering potential advantages over injectable treatments commonly used in serious fibrotic conditions.
Similar companies
Latest newsMore news →
Tvardi Therapeutics announced the publication of preclinical data in the International Journal of Molecular Sciences supporting its STAT3 inhibitors, including TTI-109, for ulcerative colitis.41d agoTvardi Therapeutics reported a net loss of $6.5 million for Q2 2026, compared with net income of $4.2 million in Q2 2025, with research and development expenses of $4.0 million and general and administrative expenses of $2.6 million.83d ago